Genfit (GNFTp)

4.74
+1.16(+32.48%)
  • Volume:
    27,938
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    4.34 - 4.74
Unusual trading volume

GNFTp Overview

Prev. Close
3.58
Day's Range
4.34-4.74
Revenue
85.58M
Open
4.48
52 wk Range
2.77-4.74
EPS
-
Volume
27,938
Market Cap
221.57M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
9,271
P/E Ratio
-
Beta
-
1-Year Change
43.64%
Shares Outstanding
49,678,477
Next Earnings Date
Sep 28, 2022
What is your sentiment on Genfit?
or
Market is currently closed. Voting is open during market hours.

Genfit News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Genfit Analysis

Genfit Company Profile

Genfit Company Profile

Employees
122
Market
France
  • Type:Equity
  • Market:France
  • ISIN:FR0004163111

Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyBuy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyBuy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyBuy
  • what's the reason of fall of Genfit?
    0
    • i also want to know
      0
    • dont worry it Will raise soon 😉
      1
  • it cheap to buy
    0
    • Trials for NASH will continue after dataset correction
      2
      • they failed the drug test and NASH drug was the only viable drug that they were developing , so practically they lost almost all value with that failure...
        1
        • not all value but a drug development. they have so many programs to continue
          0
      • damn what was wrong w this beast? from 2x all the way down to 5 w low volume?
        0
        • Whats the status , will it still go down ?
          0
          • Yes
            0
        • this baby Is the brother of contravirpharma (HEPA) .. same diseases.
          0
          • what do you mean?
            0
        • WHAT IS THE BEST STOCK TO BUY TODAY ??/ ANT RECOMMENDATION
          0
          • does anyone have an explaination for the sudden fall same day of the Nasdaq trading?
            0
            • Mathieu Gandrille ah you mean to buy because it would be oversold
              0
            • MfB Iod  i mean if 5 i would buy, and sell at 8
              0
            • Mathieu Gandrille are you a KOL?
              0
          • DATA is opn in 1Q 2019?
            0